AI, humanoid robotics & MANBRIC/biotech: the intermediate phase of the 6th Kondratieff wave

Theoretical framework. The MANBRIC concept (Medical, Additive, Nano-, Bio-, Robo-, Info-, and Cogno-technologies) formalized by Grinin & Korotayev describes the technological core of the 6th Kondratieff wave / final phase of the cybernetic revolution (2030s–2040s): the era of self-regulating systems, with medicine as the initial breakthrough sector, for demographic reasons (aging: 1 billion people over 65 by 2030), economic reasons (elasticity of health demand), and low cultural barriers to adoption. Utility for the investor: this framework prioritizes tech sub-sectors not by media narrative but by their position in the historical sequence, health/biotech as the convergence point of other technologies. Humanoid robotics, 2026 is the year the question changed. The question is no longer “can we build a humanoid” but “who defines the commercial market.” State of play mid-2026:

• Figure AI: valuation ~$39–40B, paying clients (BMW Spartanburg, 150 units in real production, 90,000+ parts, 1,250 documented hours; second Fortune 500 client), Helix VLA model at 200 Hz.

• Tesla Optimus: balance-sheet funding ($1,500B market cap), cost target of $20–30k, 5,000+ units targeted in 2026, deployment still internal, the only credible trajectory toward 1M units/year.

• Unitree: the Chinese volume player, 5,500+ humanoids delivered in 2025, G1 from ~$16k; IPO on the STAR Market in August 2026 at ~$6.2B valuation, the first pure-play listed humanoid stock.

• The geopolitical imbalance is quantified: >10,000 Chinese units delivered in 2025 vs ~600 American ones.

Disciplined quantitative reading. Goldman Sachs estimates the humanoid market at $38B by 2035; Morgan Stanley and Tesla cite >$5,000B long-term TAM; but the actual cumulative revenue of the 50+ players in 2026 remains <$500M. The projection/reality gap imposes 2026 VC discipline: only 2, 3 players will reach mass production, with a 10, 20× return dispersion within the cohort. Observed winning criteria: proprietary VLA models, in-house actuators/manufacturing, verticalized data flywheel, deep single-client deployments rather than horizontal pilots. Biotech/MANBRIC, the weak signal with strong potential. The MANBRIC logic (medicine + AI + nano + robotics convergence: robotic surgery, continuous monitoring biosensors, neural interfaces) is already verified in cost structures and pipelines. For a portfolio, the implication is a hierarchy: (1) AI infrastructure (chips, data centers, note the off-balance-sheet SPV financing risk, a topic your magazine already covers); (2) embodied robotics (the 4, 5 identified leaders); (3) convergent medtech (the central MANBRIC segment, still under-priced as such). Allocation implication: treat the humanoid as the 2018 EV thesis: position via the accessible listed leader (post-IPO Unitree) or via value chains (actuators, sensors, batteries) rather than through private valuations at $39B; monitor the only honest indicator: cumulative units delivered to external paying clients, not demos. Risks: production delays (Tesla’s history), China/US supply chain dependence (the humanoid has become a national security issue), valuation risk (Figure at $39B prices unproven software unit economics at scale).